BAFNA PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of BAFNA PHARMACEUTICALS have increased by 35.48% YoY .
The Earnings Per Share (EPS) of BAFNA PHARMACEUTICALS has increased by 116.74 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BAFNA PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 532989|NSE : BAFNAPH]
| Standalone | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹115 Cr | ₹85 Cr | ₹71 Cr | ₹42 Cr | ₹44 Cr |
| Expenses | ₹100 Cr | ₹73 Cr | ₹61 Cr | ₹41 Cr | ₹57 Cr |
| Operating Profit (Excl OI) | ₹16 Cr | ₹12 Cr | ₹10 Cr | ₹1.23 Cr | ₹-13 Cr |
| Other Income | ₹3.27 Cr | ₹1.76 Cr | ₹0.75 Cr | ₹0.26 Cr | ₹0.39 Cr |
| Interest | ₹2.04 Cr | ₹0.79 Cr | ₹0.74 Cr | ₹0.10 Cr | ₹2.13 Cr |
| Depreciation | ₹5.33 Cr | ₹5.49 Cr | ₹4.48 Cr | ₹3.27 Cr | ₹3.42 Cr |
| Profit Before Tax | ₹12 Cr | ₹5.22 Cr | ₹5.83 Cr | ₹-1.88 Cr | ₹-18 Cr |
| Profit After Tax | ₹11 Cr | ₹5.22 Cr | ₹5.83 Cr | ₹-1.88 Cr | ₹-20 Cr |
| Consolidated Net Profit | ₹11 Cr | ₹5.22 Cr | ₹5.83 Cr | ₹-25 Cr | ₹-20 Cr |
| Earnings Per Share (Rs) | ₹4.79 | ₹2.21 | ₹2.46 | ₹-7.94 | ₹-8.34 |
| PAT Margin (%) | 9.83 | 6.13 | 8.18 | -4.42 | -45.23 |
| ROE(%) | 16.75 | 8.79 | 22.26 | -22.93 | -64.36 |
| ROCE(%) | 16.12 | 8.42 | 10.62 | -2.95 | -20.90 |
| Total Debt/Equity(x) | 0.31 | 0.18 | 0.23 | -0.68 | 2.22 |
Key Financials |
||
| Market Cap | : | ₹ 200.9 Cr |
| Revenue (TTM) | : | ₹ 153.3 Cr |
| Net Profit(TTM) | : | ₹ 11.3 Cr |
| EPS (TTM) | : | ₹ 4.8 |
| P/E (TTM) | : | 17.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BAFNA PHARMACEUTICALS | -1% | -11.8% | -18% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
BAFNA PHARMACEUTICALS Revenues
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | 35.48 % |
| 5 Yr CAGR | 27.52 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹115 Cr | 35.48 | |
| Mar2022 | ₹85 Cr | 19.55 | |
| Mar2021 | ₹71 Cr | 67.68 | |
| Mar2020 | ₹42 Cr | -2.65 | |
| Mar2019 | ₹44 Cr | - | |
BAFNA PHARMACEUTICALS Operating Profit
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | 32.02 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹16 Cr | 32.02 | |
| Mar2022 | ₹12 Cr | 15.60 | |
| Mar2021 | ₹10 Cr | 737.92 | |
| Mar2020 | ₹1.23 Cr | Positive | |
| Mar2019 | ₹-13 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -2.58 % |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 13.62% | -2.58 | |
| Mar2022 | 13.98% | -3.32 | |
| Mar2021 | 14.46% | 400.35 | |
| Mar2020 | 2.89% | Positive | |
| Mar2019 | -29.95% | - | |
BAFNA PHARMACEUTICALS Profit After Tax
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | 117.33 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹11 Cr | 117.33 | |
| Mar2022 | ₹5.22 Cr | -10.47 | |
| Mar2021 | ₹5.83 Cr | Positive | |
| Mar2020 | ₹-25 Cr | Negative | |
| Mar2019 | ₹-20 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 60.36 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 9.83 % | 60.36 | |
| Mar2022 | 6.13 % | -25.06 | |
| Mar2021 | 8.18 % | Positive | |
| Mar2020 | -4.42 % | Negative | |
| Mar2019 | -45.23 % | - | |
BAFNA PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | 116.74 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹4.79 | 116.74 | |
| Mar2022 | ₹2.21 | -10.16 | |
| Mar2021 | ₹2.46 | Positive | |
| Mar2020 | ₹-7.94 | Negative | |
| Mar2019 | ₹-8.34 | - | |
BAFNA PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | 91.45 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 16.12% | 91.45 | |
| Mar2022 | 8.42% | -20.72 | |
| Mar2021 | 10.62% | Positive | |
| Mar2020 | -2.95% | Negative | |
| Mar2019 | -20.9% | - | |
BAFNA PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹84.8 |
| Current MarketCap | : | ₹ 200.9 Cr |
| Updated EOD on | : | Apr 19,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BAFNA PHARMACEUTICALS | -1% |
-11.8% |
-18% |
| SENSEX | -2.6% |
-0% |
21% |
BAFNA PHARMACEUTICALS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about BAFNA PHARMACEUTICALS Financials
How the annual revenues of BAFNA PHARMACEUTICALS have changed ?
The Revenues of BAFNA PHARMACEUTICALS have increased by 35.48% YoY .
How the Earnings per Share (EPS) of BAFNA PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of BAFNA PHARMACEUTICALS has increased by 116.74 % YoY .
Check out Intrinsic Value of Peers of BAFNA PHARMACEUTICALS
Compare Stock Analytics of Peers of BAFNA PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
